Sartorius AG SRT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if SRT is a good fit for your portfolio.
News
-
Sartorius Shares Slide on Revenue, Profit Decline
-
Sartorius Stedim Biotech Completes $1.3 Billion Capital Increase
-
Sartorius Stock Climbs After Sales, Earnings Beat Expectations
-
Sartorius Shares Rise on Signs of Order Recovery in 3Q
-
Sartorius's Shares Drop on Outlook Cut, Preliminary 3Q Declines
-
Sartorius Cuts 2023 Guidance on Lower Preliminary Sales Results
-
Sartorius Issues $3.22 Billion in Bonds for Polyplus Bridge Financing
-
Sartorius Names Florian Funck as New CFO
Trading Information
- Previous Close Price
- €219.00
- Day Range
- €218.00–227.50
- 52-Week Range
- €181.00–310.50
- Bid/Ask
- €225.50 / €0.00
- Market Cap
- €15.53 Bil
- Volume/Avg
- 2,590 / 4,658
Key Statistics
- Price/Earnings (Normalized)
- 125.45
- Price/Sales
- 2.35
- Dividend Yield (Trailing)
- 0.32%
- Dividend Yield (Forward)
- 0.32%
- Total Yield
- 0.32%
Company Profile
Sartorius AG is a leading provider of bioprocessing solutions. Its Bioprocess division sells equipment and consumables for upstream and downstream manufacturing of biologic drugs, and has a focus on single-use technology, or SUT. Its Lab Products and Services division offers a wide range of products for lab use, including scales, pipettes, and filtration equipment. As of 2022, the Bioprocess and LPS divisions contributed 80% and 20% of revenue, respectively. Bioprocess is housed in its subsidiary Sartorius Stedim Biotech, of which Sartorius AG has a 74% ownership and 85% voting control. The business is geographically diverse, with revenue across Europe, the Middle East, and Africa (37% of 2022 sales), the Americas (37%), and Asia-Pacific (26%). We estimate China revenue to be around 10%.
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Stock Style Box
- Large Growth
- Total Number of Employees
- 14,338
- Website
- https://www.sartorius.com
Competitors
Valuation
|
Metric
|
SRT
|
MRK
|
MTD
|
|---|---|---|---|
Price/Earnings (Normalized) | 125.45 | 19.58 | 32.51 |
Price/Book Value | 5.81 | 2.45 | — |
Price/Sales | 2.35 | 3.11 | 7.18 |
Price/Cash Flow | 15.29 | 14.53 | 29.75 |
Price/Earnings
SRT
MRK
MTD
Financial Strength
|
Metric
|
SRT
|
MRK
|
MTD
|
|---|---|---|---|
Quick Ratio | 1.19 | 0.79 | 0.62 |
Current Ratio | 2.02 | 1.42 | 1.04 |
Interest Coverage | 2.34 | 11.32 | 13.59 |
Quick Ratio
SRT
MRK
MTD
Profitability
|
Metric
|
SRT
|
MRK
|
MTD
|
|---|---|---|---|
Return on Assets (Normalized) | 2.26% | 7.55% | 24.53% |
Return on Equity (Normalized) | 9.30% | 13.81% | — |
Return on Invested Capital (Normalized) | 4.67% | 10.19% | 44.03% |
Return on Assets
SRT
MRK
MTD
Medical Instruments & Supplies Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
ISRG
| Intuitive Surgical Inc | Gvpfbsnmy | Xftx | $133.1 Bil | |
BDX
| Becton Dickinson & Co | Lrqbphsz | Vwbrbrh | $66.9 Bil | |
ALC
| Alcon Inc | Kqjdxgp | Qgnthtb | $38.9 Bil | |
RMD
| ResMed Inc | Ktmsnzyvc | Dvdmt | $32.1 Bil | |
CLPBY
| Coloplast A/S ADR | Tfnykjrdpw | Wnvw | $27.9 Bil | |
WST
| West Pharmaceutical Services Inc | Rpbkdbjnwj | Rydfh | $26.4 Bil | |
BAX
| Baxter International Inc | Mdswwpxwg | Qnztjs | $20.4 Bil | |
HOLX
| Hologic Inc | Fqnpqrql | Khsghp | $17.8 Bil | |
COO
| The Cooper Companies Inc | Wdzrxhd | Yxxqsw | $17.7 Bil | |
TFX
| Teleflex Inc | Lxnb | Jxln | $9.7 Bil |